<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877210</url>
  </required_header>
  <id_info>
    <org_study_id>PPUKM</org_study_id>
    <nct_id>NCT04877210</nct_id>
  </id_info>
  <brief_title>Effects of Topical Insulin on Levels of Tear Inflammatory Mediators</brief_title>
  <official_title>Effects of Topical Insulin on Levels of Tear Inflammatory Mediators Compared to Standard Artificial Tears and Normal Saline in Diabetics With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 samples are take to determine the effects of topical insulin on tear inflammatory&#xD;
      mediators interleukin 1a, interleukin 6 and matrix metalloprotenase 9 in diabetics with dry&#xD;
      eye disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tear samples are taken to compare the levels of inflammatory markers (IL 1a, IL6 and MMP 9)&#xD;
      pre-and post treatment with topical insulin in normal saline compared to standard therapy and&#xD;
      normal saline in diabetics with dry eyes and also to correlate the IL 1a, IL6 and MMP 9&#xD;
      levels with clinical outcomes in diabetics with dry eyes treated with topical insulin in&#xD;
      normal saline, standard therapy and normal saline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">January 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical marker 1</measure>
    <time_frame>4 weeks</time_frame>
    <description>Interleuikn 1-alpha</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical marker 2</measure>
    <time_frame>4 weeks</time_frame>
    <description>Interleukin 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical marker 3</measure>
    <time_frame>4 weeks</time_frame>
    <description>Matrix metallo-proteinase 9</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Topical Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin (Actrapid) diluted in normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline eyedrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Artifical Tear</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gutt systane ultra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Insulin</intervention_name>
    <description>Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>Standard Artifical Tear</arm_group_label>
    <arm_group_label>Topical Insulin</arm_group_label>
    <other_name>Gutt insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all diabetics aged 18 - 50 years of age with at least mild OSDI scores&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetics on contact lenses&#xD;
&#xD;
          -  Diabetic with history of ocular surgery in the preceding 3 months&#xD;
&#xD;
          -  Post menopausal women&#xD;
&#xD;
          -  Known mild dry eye with prior usage of topical therapy who are unable to discontinue&#xD;
&#xD;
          -  Known case of allergic eye disease&#xD;
&#xD;
          -  Sjogren's syndrome patients&#xD;
&#xD;
          -  Unwilling or unable to attend 6 follow up and sampling sessions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mae-Lynn C. Bastion</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPUKM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atikah bt Asini, M.D.</last_name>
    <phone>+60178254335</phone>
    <email>atikahasini@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPUKM</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atikah Asini, M.D.</last_name>
      <phone>+60178254335</phone>
      <email>atikahasini@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Kebangsaan Malaysia Medical Centre</investigator_affiliation>
    <investigator_full_name>Mae-Lynn Catherine Bastion</investigator_full_name>
    <investigator_title>Professor Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

